High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan.

ABSTRACT:

SUBMITTER: Nieto Y 

PROVIDER: S-EPMC5844223 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature